Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment - Results from 12 countries in EuroSpA
- Brahe, Cecilie Heegaard
- Ørnbjerg, Lykke Midtbøll
- Jacobsson, Lennart
- Nissen, Michael J.
- Kristianslund, Eirik Klami
- Mann, Herman
- Santos, Maria José
- Reino, Juan Gómez
- Nordström, Dan
- Rotar, Ziga
- Gudbjornsson, Bjorn
- Onen, Fatos
- Codreanu, Catalin
- Lindström, Ulf
- Möller, Burkhard
- Kvien, Tore K.
- Pavelka, Karel
- Barcelos, Anabela
- Sánchez-Piedra, Carlos
- Eklund, Kari K.
- Tomšič, Matija
- Love, Thorvardur Jon
- Can, Gercek
- Ionescu, Ruxandra
- Loft, Anne Gitte
- Van Der Horst-Bruinsma, I. E.
- MacFarlane, Gary J.
- Iannone, Florenzo
- Hyldstrup, Lise Hejl
- Krogh, Niels Steen
- Østergaard, Mikkel
- Hetland, Merete Lund
DOIAbstract
To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naïve patients with PsA. Methods: Prospectively collected data on PsA patients in routine care from 12 European registries were pooled. Heterogeneity in baseline characteristics between registries were explored (analysis of variance and pairwise comparison). Retention rates (Kaplan-Meier), clinical remission [28-joint count DAS (DAS28) 14 000 patients with PsA who initiated first TNFi treatment in routine care were in DAS28 remission after 6 months, and three-quarters were still on the drug after 1 year. Considerable heterogeneity in baseline characteristics and outcomes across registries was observed. The feasibility of creating a large European database ...
Add to ORKG